2-phenyl-1,3-thiazol-5-amine | 87657-91-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-phenyl-1,3-thiazol-5-amine
• CAS: 87657-91-8
• 化学式: C₉H₈N₂S
• mdl: MFCD11847092
• 分子量: 176.242
• InChiKey: CFLMSQYWGWBIHE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-phenyl-1,3-thiazol-5-amine 在 三氟乙酸 作用下， 以 甲醇 为溶剂， 反应 1.5h， 生成 1-[(2-Phenyl-1,3-thiazol-5-yl)-prop-2-ynoylamino]cyclopentane-1-carboxamide
  参考文献：
  名称：

  [EN] GPX4 INHIBITORS AND USE THEREOF
  [FR] INHIBITEURS DE GPX4 ET LEUR UTILISATION

  摘要：

  The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, specifically in treating cancer or autoimmune diseases. This disclosure also features a composition containing the same as well as methods of using and making the same.

  公开号：

  WO2024030651A1
• 作为产物：
  描述：

  2-苯基噻唑-5-羧酸 在 盐酸 、 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 3.0h， 生成 2-phenyl-1,3-thiazol-5-amine
  参考文献：
  名称：

  [EN] GPX4 INHIBITORS AND USE THEREOF
  [FR] INHIBITEURS DE GPX4 ET LEUR UTILISATION

  摘要：

  The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, specifically in treating cancer or autoimmune diseases. This disclosure also features a composition containing the same as well as methods of using and making the same.

  公开号：

  WO2024030651A1

文献信息

• Fragment-Based Discovery of Irreversible Covalent Inhibitors of Cysteine Proteases Using Chlorofluoroacetamide Library
  作者：Chizuru Miura、Naoya Shindo、Kei Okamoto、Keiko Kuwata、Akio Ojida

  DOI：10.1248/cpb.c20-00547

  日期：2020.11.1

  CFA-appended compounds and applied it to the covalent ligand screening for cysteine protease papain as a model protein target. Using the fluorescence enzymatic assay, we identified CFA-benzothiazole 30 as a papain inhibitor, which was found to irreversibly inactivate papain upon enzyme kinetic analysis. The formation of the covalent papain-30 adduct was confirmed using electrospray ionization mass spectrometry

  基于片段的方法与亲电反应性化合物相结合是一种强大的策略，可以发现针对蛋白质靶标的新型共价配体。然而，混杂反应性经常干扰具有对靶蛋白的特异性结合亲和力的片段的鉴定。在我们的研究中，我们报告了使用化学调谐的氯氟乙酰胺（CFA）的弱反应性发现基于片段的共价药物。我们构建了一个由30个CFA附加化合物组成的小片段文库，并将其应用于半胱氨酸蛋白酶木瓜蛋白酶作为模型蛋白靶标的共价配体筛选。使用荧光酶促测定，我们鉴定出CFA-苯并噻唑30为木瓜蛋白酶抑制剂，经酶动力学分析发现它可逆地使木瓜蛋白酶失活。使用电喷雾电离质谱分析法确认了共价木瓜蛋白酶30加合物的形成。基于活性的蛋白质谱分析（ABPP）实验使用了30（即30炔）的炔基化类似物，表明30炔共价标记的木瓜蛋白酶具有很高的选择性。这些数据证明了CFA片段文库在从头发现靶标选择性共价抑制剂的潜在效用。
• Reactions with Heterocyclic Arylazo Compounds: Synthesis of New 1-Azoloylimidazolones
  作者：Hassan A. Elfahham、Ibraheim Elsakka、Nadia R. Mohamed、Mohamed H. Elnagdi

  DOI：10.1002/ardp.19833160912

  日期：——

  Several new carboxamide derivatives of 1‐azoloylimidazolones and 1‐aryl‐1,2,4‐triazolones were synthesised by reaction of 2‐alkoxy‐4‐benzylidene‐2‐thiazolin‐5‐ones and 2‐alkoxy‐4‐phenylhydrazone‐2‐thiazolin‐5‐ones with heterocyclic amines.

  通过2-烷氧基-4-亚苄基-2-噻唑啉-5-酮和2-烷氧基-苯腙-4-三唑酮的反应合成了1-唑基咪唑酮和1-芳基-1,2,4-三唑酮的几种新型羧酰胺衍生物2-Thiazolin-5-ones 与杂环胺。
• TYROSINE PHOSPHATASE INHIBITORS AND USES THEREOF TO MODULATE THE ACTIVITY OF ENZYMESp INVOLVED IN THE PATHOLOGY OF MYCOBACTERIUM TUBERCULOSIS
  申请人：Zhang Zhong-Yin

  公开号：US20140179735A1

  公开（公告）日：2014-06-26

  A variety of benzofurans and indole derivatives some with an alkynyl linker are disclosed herein. These compounds are not highly charged at physiological pH and have good bioavailability characteristics. These compounds exhibit selective or at least preferential affinity for the active sites of various sub-sets of protein tyrosine phosphatases. Some of these compounds are excellent inhibitors of Mycobacterium protein tyrosine phosphatase B (mPTPB) a protein tyrosine phosphatase expressed in Mycobacterium tuberculosis and characterized as a virulence factor in the causal agent of tuberculosis. Accordingly, many of these compounds and pharmaceutically acceptable salts thereof are useful for the treatment of diseases such as tuberculosis.

  本文介绍了一系列苯并呋喃和吲哚衍生物，其中一些具有炔基连接物。这些化合物在生理pH值下电荷不高，具有良好的生物利用度特性。这些化合物表现出对各种亚集蛋白酪氨酸磷酸酶的活性位点具有选择性或至少具有优先亲和性。其中一些化合物是良好的Mycobacterium蛋白酪氨酸磷酸酶B（mPTPB）的抑制剂，这是一种在结核病的病原体Mycobacterium tuberculosis中表达的蛋白酪氨酸磷酸酶，并被认为是一种毒力因子。因此，这些化合物和其药学上可接受的盐对于治疗结核病等疾病非常有用。
• NOVEL COMPOUNDS
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20160263122A1

  公开（公告）日：2016-09-15

  The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: L A represents an optionally substituted methylene or ethylene group; L B represents —N(H)—C(═0)- or —C(═0)—N(H)—; R 1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R 2 represents an optionally substituted 5- or 6-membered heteroaryl group; R 3 represents an optionally substituted phenyl group.

  本发明涉及一般式（I）所描述和定义的取代N-苯基-杂环基-3-乙酰氨基苯甲酰胺和N-[3-(乙酰氨基)苯基]-苯基-杂环基-羧酰胺，以制备该化合物的方法，用于制备该化合物的中间体化合物，包含该化合物的制药组合物和组合物，以及用于制造治疗或预防癌症等疾病的制药组合物的使用，其中：LA表示可选择取代的亚甲基或乙烯基；LB表示-N(H)-C(═0)-或-C(═0)-N(H)-；R1表示可选择取代的5-至8-成员杂环烷基，4-至10-成员杂环烷基烯基，芳基，杂环芳基或-N(R7)(Ci-C6-烷基)基团；R2表示可选择取代的5-或6-成员杂环基团；R3表示可选择取代的苯基团。
• Compounds
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US10130633B2

  公开（公告）日：2018-11-20

  The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: LA represents an optionally substituted methylene or ethylene group; LB represents —N(H)—C(═O)— or —C(═O)—N(H)—; R1 represents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or —N(R7)(Ci-C6-alkyl) group; R2 represents an optionally substituted 5- or 6-membered heteroaryl group; R3 represents an optionally substituted phenyl group.

  本发明涉及本文所述和定义的通式(I)的取代的N-(苯基-异芳基)-3-乙酰氨基苯甲酰胺和N-[3-(乙酰氨基)苯基]-苯基-异芳基-甲酰胺，涉及制备所述化合物的方法，涉及制备所述化合物有用的中间化合物，涉及包含所述化合物的药物组合物和组合物，涉及使用所述化合物制造治疗或预防诸如癌症等疾病的药物组合物，其中i.a.: LA 代表任选取代的亚甲基或亚乙基； LB 代表-N(H)-C(═O)-或-C(═O)-N(H)-； R1 代表任选取代的 5 至 8 元杂环烷基、4 至 10 元杂环烯基、芳基、杂芳基或 -N(R7)(Ci-C6-烷基)基团； R2 代表任选取代的 5 或 6 元杂芳基； R3 代表任选取代的苯基。